Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest Amides Stories

2014-01-16 23:01:30

The Firm is investigating Pradaxa lawsuits on behalf of individuals treated with the blood thinner who allegedly suffered life-threatening episodes of internal bleeding due to its use. New York, New York (PRWEB) January 16, 2014 Bernstein Liebhard LLP continues to monitor developments involving the thousands of Pradaxa lawsuits (http://www.pradaxalawsuithelp.com/ ) filed on behalf of individuals who allegedly suffered life-threatening episodes of internal bleeding due to their use of the...

2014-01-13 08:30:13

Topline Data Will Be Presented at Biotech Showcase HEIDELBERG, Germany, Jan. 13, 2014 /PRNewswire/ -- Apogenix, a clinical stage biopharmaceutical company, announced today the successful completion of its phase II proof-of-concept trial with APG101 in patients with recurrent glioblastoma. All endpoints of the randomized controlled trial that compared the efficacy and safety of a combination therapy of APG101 and radiotherapy versus radiotherapy alone were achieved or...

2014-01-09 23:25:52

http://www.DrugNews.net is the web’s premier source for prescription device warnings, research, side effects and legal news. Visit the DrugNews Center today. Chicago, IL (PRWEB) January 09, 2014 The DrugNews prescription drug safety center has added new information for patients who’ve taken the blood thinner Pradaxa. The FDA has ordered a new review of user data in order to assess the safety of the drug*. The news comes as court records revealed the number of lawsuits alleging the...

2014-01-06 23:02:11

The Firm is evaluating Pradaxa lawsuits on behalf of individuals who suffered serious occurrences of internal bleeding, allegedly due to their use of the blood thinner. New York, New York (PRWEB) January 06, 2014 As Pradaxa lawsuits (http://www.pradaxalawsuithelp.com/) continue to move forward in courts around the country, Bernstein Liebhard LLP notes that the U.S. Food & Drug Administration (FDA) is planning a large scale assessment of Pradaxa bleeding rates. In a posting on an...

2013-12-20 23:23:06

National network of attorneys will continue to accept inquiries through New Year's Day about legal options to seek compensation over allegations that Pradaxa may cause bleeding problems. San Diego, CA (PRWEB) December 20, 2013 http://www.resource4thepeople.com/defectivedrugs/pradaxa-lawsuits.html Resource4thePeople announced today that its national network of attorneys will be available over the upcoming holiday season to consumers inquiring about litigation involving allegations that...

2013-12-17 08:28:51

RE-COVER II(TM) trial shows dabigatran non-inferior to warfarin in preventing recurrent DVT and/or PE and related death, with a reduction in major or clinically relevant non-major bleeding RIDGEFIELD, Conn., Dec. 17, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from the RE-COVER(TM) II study evaluating dabigatran compared to warfarin in patients diagnosed with acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE). In this Phase III study,...

2013-12-10 23:19:52

Reportbuyer.com just published a new market research report: PharmaPoint: Type 2 Diabetes - Brazil Drug Forecast and Market Analysis to 2022. London (PRWEB) December 10, 2013 PharmaPoint: Type 2 Diabetes - Brazil Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Type 2 Diabetes - Brazil Drug Forecast and Market Analysis to 2022”. The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being...

2013-12-10 23:19:45

Reportbuyer.com just published a new market research report: PharmaPoint: Type 2 Diabetes - India Drug Forecast and Market Analysis to 2022. London (PRWEB) December 10, 2013 PharmaPoint: Type 2 Diabetes - India Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Type 2 Diabetes - India Drug Forecast and Market Analysis to 2022”. The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked...

2013-12-10 23:19:39

Reportbuyer.com just published a new market research report: PharmaPoint: Type 2 Diabetes - China Drug Forecast and Market Analysis to 2022. London (PRWEB) December 10, 2013 PharmaPoint: Type 2 Diabetes - China Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Type 2 Diabetes - China Drug Forecast and Market Analysis to 2022”. The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked...

2013-12-10 23:04:36

Reportbuyer.com just published a new market research report: PharmaPoint: Type 2 Diabetes - UK Drug Forecast and Market Analysis to 2022. London (PRWEB) December 10, 2013 PharmaPoint: Type 2 Diabetes - UK Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Type 2 Diabetes - UK Drug Forecast and Market Analysis to 2022”. The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a...